Project Grant R42AA032207
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$423K
Federal Agency
National Institute on Alcohol Abuse and Alcoholism
Awardee
Biosymetrics Inc. (LMF2M1E82Q97)
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
Huntington, NY, USA
Similar Awards
This $499,987 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund the development of a High Throughput Alcohol Screening Platform (HT-ASP) that incorporates cortical organoids. The project aims to create an automated platform to mature, maintain, and assay over 100 organoids in culture, providing a robust and genetically diverse system for screening potential alcohol use disorder therapeutics. The...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,373,036 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University. The overarching goal of this 5-year research project (Sep 2024 - Aug 2029) is to enhance the understanding and prediction of heavy drinking episodes during initial recovery from alcohol use disorder (AUD). The project aims to leverage wearable biosensor technology and artificial intelligence to develop real-time predictive...
This Project Grant award of $594,784 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a postmortem, multi-omic study of brains from 341 total subjects to identify novel lasting transcriptomic and epigenetic changes in biological pathways that may serve as biomarkers and therapeutic targets for alcohol use disorder (AUD). The research will analyze RNA sequencing and whole-genome bisulfite sequencing data across 8 brain...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, will support the development and testing of a novel in vivo model called CHIMERA-BONCAT. This model will enable comprehensive, unbiased, and cell-type-specific characterization of the human microglial response to alcohol exposure. The $214,385 award, with a period of performance from August 2024 to July 2026, will fund research...
This Cooperative Agreement award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $999,393.00 to support Investigational New Drug (IND)-enabling studies for a novel therapeutic targeting the hypothalamic-pituitary-adrenal (HPA) axis for the treatment of Alcohol Use Disorder (AUD). The awardee, Stress Therapeutics, Inc., a for-profit company in San Diego, California, will manufacture and validate the test article,...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, will support the development of novel 3D human brain circuits to investigate the role of microglia in alcohol use disorder (AUD) and Alzheimer's disease (AD) pathology. The $223,531 award to the University of North Carolina at Chapel Hill will fund research to elucidate how alcohol-induced changes in microglial metabolism...
This Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program, aims to investigate the neural mechanisms driving adaptive stress coping behaviors and subsequent alcohol use. The $498,121.57 award, effective August 15, 2024 through July 31, 2027, will utilize an animal model to explore how dysfunction in the corticolimbic circuitry, specifically the prelimbic cortex and basolateral...
This Project Grant award of $397,829 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of an AI platform to discover new therapeutics for substance use disorders (SUDs). The key products and services to be delivered include: Creating a set of curated training datasets and machine learning (ML) models to accelerate drug discovery tasks for SUDs. Identifying mechanistic targets related to the...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) funding opportunity, supports the investigational new drug development of noribogaine for the treatment of alcohol use disorder (AUD). The awardee, Demerx, Inc., a Miami-based clinical stage drug development company, will use the $914,324 in funding awarded on August 1, 2025 to conduct IND-enabling nonclinical studies, including subchronic repeat...
This $366,406 Project Grant was awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to Yale University. The grant will be used to develop two novel human laboratory models to screen potential medications for Alcohol Use Disorder (AUD). The first model will assess a medication's ability to increase abstinence and reduce heavy drinking, which align with key FDA endpoints for AUD medication approval. The second model will...